Last reviewed 2026-04-19 · How we verify

varenicline (CP-526,555)

Pfizer · Phase 3 active Small molecule

varenicline (CP-526,555) is a Small molecule drug developed by Pfizer. It is currently in Phase 3 development. Also known as: Chantix, Champix.

At a glance

Generic name	varenicline (CP-526,555)
Also known as	Chantix, Champix
Sponsor	Pfizer
Modality	Small molecule
Phase	Phase 3

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Assessment of Safety and Efficacy of Varenicline in Patients That Wish to Stop Smoking (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

varenicline (CP-526,555) CI brief — competitive landscape report
varenicline (CP-526,555) updates RSS · CI watch RSS
Pfizer portfolio CI

Frequently asked questions about varenicline (CP-526,555)

What is varenicline (CP-526,555)?

varenicline (CP-526,555) is a Small molecule drug developed by Pfizer.

Who makes varenicline (CP-526,555)?

varenicline (CP-526,555) is developed by Pfizer (see full Pfizer pipeline at /company/pfizer).

Is varenicline (CP-526,555) also known as anything else?

varenicline (CP-526,555) is also known as Chantix, Champix.

What development phase is varenicline (CP-526,555) in?

varenicline (CP-526,555) is in Phase 3.

Manufacturer: Pfizer — full pipeline
Also known as: Chantix, Champix
Compare: varenicline (CP-526,555) vs similar drugs
Pricing: varenicline (CP-526,555) cost, discount & access